Inhibition of Hsp90 with synthesis macrolactones: Synthesis and structural and biological evaluation of ring and conformational analogs of radicicol

被引:57
作者
Proisy, Nicolas
Sharp, Swee Y.
Boxall, Kathy
Connelly, Stephen
Roe, S. Mark
Prodromou, Chrisostomos
Slawin, Alexandra M. Z.
Pearl, Laurence H.
Workman, Paul
Moody, Christopher J.
机构
[1] Univ Nottingham, Sch Chem, Nottingham NG7 2RD, England
[2] Inst Canc Res, Canc Res UK Ctr Canc Therapeut, Haddow Labs, Sutton SM2 5NG, Surrey, England
[3] Univ Exeter, Dept Chem, Exeter EX4 4QD, Devon, England
[4] Inst Canc Res, Sect Struct Biol, Chester Beatty Labs, London SW3 6JB, England
[5] Univ St Andrews, Sch Chem, St Andrews KY16 9ST, Fife, Scotland
来源
CHEMISTRY & BIOLOGY | 2006年 / 13卷 / 11期
基金
英国惠康基金;
关键词
D O I
10.1016/j.chembiol.2006.09.015
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
A series of benzo-macrolactones of varying ring size and conformation has been prepared by chemical synthesis and evaluated by structural and biological techniques. Thus, 12- to 16-membered lactones were obtained by concise routes, involving ring-closing metathesis as a key step. In enzyme assays, the 13-, 15-, and 16-membered analogs are good inhibitors, suggesting that they can adoptthe required conformation to fit in the ATP-binding site. This was confirmed by cocrystallization of 13-, 14-, and 15-membered lactones with the N-terminal domain of yeast Hsp90, showing that they bind similarly to the "natural" 14-membered radicicol. The most active compounds in the ATPase assays also showed the greatest growth-inhibitory potency in HCT116 human colon cancer cells and the established molecular signature of Hsp90 inhibition, i.e., depletion of client proteins with upregulation of Hsp70.
引用
收藏
页码:1203 / 1215
页数:13
相关论文
共 65 条
  • [61] Combinatorial attack on multistep oncogenesis by inhibiting the Hsp90 molecular chaperone
    Workman, P
    [J]. CANCER LETTERS, 2004, 206 (02) : 149 - 157
  • [62] Structure-activity relationships in purine-based inhibitor binding to HSP90 isoforms
    Wright, L
    Barril, X
    Dymock, B
    Sheridan, L
    Surgenor, A
    Beswick, M
    Drysdale, M
    Collier, A
    Massey, A
    Davies, N
    Fink, A
    Fromont, C
    Aherne, W
    Boxall, K
    Sharp, S
    Workman, P
    Hubbard, RE
    [J]. CHEMISTRY & BIOLOGY, 2004, 11 (06): : 775 - 785
  • [63] Total synthesis as a resource in the discovery of potentially valuable antitumor agents: Cycloproparadicicol
    Yamamoto, K
    Garbaccio, RM
    Stachel, SJ
    Solit, DB
    Chiosis, G
    Rosen, N
    Danishefsky, SJ
    [J]. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION, 2003, 42 (11) : 1280 - 1284
  • [64] New efficient synthesis of resorcinylic macrolides via ynolides: Establishment of cycloproparadicicol as synthetically feasible preclinical anticancer agent based on Hsp90 as the target
    Yang, ZQ
    Geng, XD
    Solit, D
    Pratilas, CA
    Rosen, N
    Danishefsky, SJ
    [J]. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2004, 126 (25) : 7881 - 7889
  • [65] Hsp90 inhibitors identified from a library of novobiocin analogues
    Yu, XM
    Shen, G
    Neckers, L
    Blake, H
    Holzbeierlein, J
    Cronk, B
    Blagg, BSJ
    [J]. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2005, 127 (37) : 12778 - 12779